Your browser is no longer supported. Please, upgrade your browser.
Revolution Medicines, Inc.
Index- P/E- EPS (ttm)-2.37 Insider Own0.50% Shs Outstand73.54M Perf Week-12.51%
Market Cap1.50B Forward P/E- EPS next Y-2.71 Insider Trans-1.46% Shs Float72.77M Perf Month-22.74%
Income-168.60M PEG- EPS next Q-0.64 Inst Own99.40% Short Float11.31% Perf Quarter-33.21%
Sales28.70M P/S52.25 EPS this Y-91.70% Inst Trans0.00% Short Ratio16.89 Perf Half Y-30.62%
Book/sh8.68 P/B2.29 EPS next Y-8.40% ROA-23.40% Target Price36.00 Perf Year-52.85%
Cash/sh8.07 P/C2.46 EPS next 5Y- ROE-26.80% 52W Range19.82 - 56.18 Perf YTD-21.06%
Dividend- P/FCF- EPS past 5Y- ROI-23.20% 52W High-64.63% Beta-
Dividend %- Quick Ratio12.00 Sales past 5Y- Gross Margin- 52W Low0.28% ATR1.78
Employees162 Current Ratio12.00 Sales Q/Q-91.30% Oper. Margin- RSI (14)30.00 Volatility10.41% 7.93%
OptionableYes Debt/Eq0.00 EPS Q/Q-71.60% Profit Margin- Rel Volume1.67 Prev Close19.98
ShortableYes LT Debt/Eq0.00 EarningsNov 10 AMC Payout- Avg Volume487.19K Price19.87
Recom2.10 SMA20-16.48% SMA50-22.77% SMA200-32.64% Volume812,737 Change-0.55%
Sep-23-21Initiated Stifel Hold $34
Aug-12-21Downgrade Goldman Buy → Neutral $49 → $27
May-18-21Initiated Goldman Buy $49
May-21-20Initiated H.C. Wainwright Buy $55
Mar-09-20Initiated JP Morgan Neutral $32
Mar-09-20Initiated Guggenheim Buy $50
Mar-09-20Initiated Cowen Outperform
Jan-11-22 02:15PM  
Jan-04-22 07:30AM  
Nov-24-21 07:30AM  
Nov-10-21 05:55PM  
Nov-08-21 04:05PM  
Nov-04-21 03:01PM  
Nov-03-21 04:05PM  
Oct-27-21 04:50AM  
Oct-18-21 04:58AM  
Sep-30-21 07:30AM  
Sep-15-21 07:30AM  
Sep-07-21 04:05PM  
Aug-13-21 05:02AM  
Aug-11-21 05:25PM  
Aug-04-21 04:05PM  
Aug-02-21 03:01PM  
Jul-13-21 08:51AM  
Jun-24-21 04:05PM  
Jun-10-21 07:30AM  
Jun-02-21 07:30AM  
May-18-21 07:30AM  
May-12-21 05:31AM  
May-10-21 06:15PM  
May-06-21 03:01PM  
May-03-21 07:05AM  
Apr-21-21 07:00AM  
Apr-12-21 08:43AM  
Apr-02-21 06:15AM  
Mar-11-21 04:05PM  
Mar-09-21 07:30AM  
Mar-02-21 04:05PM  
Feb-18-21 07:30AM  
Feb-09-21 07:43AM  
Feb-08-21 04:01PM  
Feb-04-21 07:54AM  
Feb-03-21 11:30PM  
Feb-01-21 04:01PM  
Jan-05-21 07:30AM  
Dec-15-20 10:16PM  
Nov-26-20 02:41AM  
Nov-12-20 07:30AM  
Oct-24-20 09:45AM  
Oct-12-20 07:30AM  
Sep-22-20 08:52AM  
Sep-18-20 04:16PM  
Sep-16-20 09:00AM  
Sep-09-20 07:30AM  
Sep-08-20 07:30AM  
Aug-28-20 11:12AM  
Aug-10-20 07:30AM  
Jul-13-20 04:01PM  
Jul-06-20 04:01PM  
Jun-30-20 04:05PM  
Jun-22-20 04:01PM  
Jun-18-20 07:30AM  
Jun-09-20 07:30AM  
May-22-20 10:29PM  
May-19-20 07:30AM  
May-14-20 04:05PM  
Apr-29-20 08:05AM  
Mar-18-20 07:30AM  
Mar-09-20 07:30AM  
Feb-18-20 04:01PM  
Feb-14-20 01:24PM  
Feb-13-20 11:20AM  
Feb-12-20 07:56PM  
Feb-11-20 07:12AM  
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anders JackSee RemarksDec 17Sale24.411704,1508,434Dec 21 04:34 PM
Wang XiaolinSee RemarksDec 17Sale24.412576,27311,938Dec 21 04:33 PM
Horn Margaret ASee RemarksDec 17Sale24.4149111,98525,508Dec 21 04:31 PM
Kelsey Stephen MichaelSee RemarksDec 17Sale24.413438,373251,815Dec 21 04:32 PM
GOLDSMITH MARK ASee RemarksDec 17Sale24.411,57138,34882,622Dec 21 04:30 PM
GOLDSMITH MARK ASee RemarksDec 06Option Exercise0.4937,72118,48384,193Dec 08 04:16 PM
Anders JackSee RemarksSep 17Sale30.021664,9838,192Sep 21 07:48 PM
Wang XiaolinSee RemarksSep 17Sale30.022507,50512,195Sep 21 07:47 PM
Kelsey Stephen MichaelSee RemarksSep 17Sale30.0233510,057252,158Sep 21 07:48 PM
Horn Margaret ASee RemarksSep 17Sale30.0247914,38025,999Sep 21 07:46 PM
GOLDSMITH MARK ASee RemarksSep 17Sale30.021,53145,96146,472Sep 21 07:47 PM
Wang XiaolinSee RemarksJun 17Sale34.122438,29112,445Jun 22 05:19 PM
GOLDSMITH MARK ASee RemarksJun 17Sale34.121,48550,67048,003Jun 22 05:17 PM
Horn Margaret ASee RemarksJun 17Sale34.1346415,83526,478Jun 22 05:18 PM
Kelsey Stephen MichaelSee RemarksJun 17Sale34.1232411,056252,493Jun 22 05:18 PM
Anders JackSee RemarksJun 17Sale34.121605,4608,358Jun 22 05:16 PM
Third Rock Ventures II, L.P.10% OwnerJun 04Sale30.23164,9964,987,8290Jun 07 06:10 PM
Third Rock Ventures II, L.P.10% OwnerJun 03Sale30.20378,11711,419,133164,996Jun 07 06:10 PM
Third Rock Ventures II, L.P.10% OwnerMay 26Sale30.531,231,20437,588,658543,113May 27 05:43 PM
Third Rock Ventures II, L.P.10% OwnerMay 25Sale30.93135,0004,175,5501,774,317May 27 05:43 PM
Svennilson PeterDirectorApr 28Sale42.501004,2501,571,963Apr 28 07:31 PM
Svennilson PeterDirectorApr 27Sale42.6523,326994,9221,572,010Apr 28 07:31 PM
Svennilson PeterDirectorApr 26Sale42.8552,9842,270,1741,582,965Apr 28 07:31 PM
Svennilson PeterDirectorApr 09Sale43.8324,7011,082,5411,607,848Apr 12 05:41 PM
Svennilson PeterDirectorApr 08Sale44.8046,2282,071,2041,619,448Apr 12 05:41 PM
Svennilson PeterDirectorApr 07Sale45.6027,9531,274,7831,641,158Apr 07 06:23 PM
Svennilson PeterDirectorApr 06Sale48.0639,5001,898,4411,654,286Apr 07 06:23 PM
Svennilson PeterDirectorApr 05Sale46.6518,215849,8171,672,837Apr 07 06:23 PM
Miller Vincent A.DirectorMar 22Option Exercise4.733,20015,13623,333Mar 24 06:11 PM
Miller Vincent A.DirectorMar 22Sale49.003,200156,80020,133Mar 24 06:11 PM
GOLDSMITH MARK ASee RemarksMar 01Option Exercise1.125,0005,6005,744Mar 03 06:06 PM
GOLDSMITH MARK ASee RemarksMar 01Sale46.005,000229,981744Mar 03 06:06 PM
Horn Margaret ASee RemarksFeb 05Option Exercise4.7335,000165,55046,198Feb 08 07:06 PM
GOLDSMITH MARK ASee RemarksFeb 05Option Exercise1.1215,00016,80015,744Feb 08 07:06 PM
GOLDSMITH MARK ASee RemarksFeb 05Sale55.0015,000825,000744Feb 08 07:06 PM
Horn Margaret ASee RemarksFeb 05Sale55.0035,0001,925,00011,198Feb 08 07:06 PM
Weber BarbaraDirectorFeb 04Option Exercise4.735,00023,6506,808Feb 05 08:09 PM
Weber BarbaraDirectorFeb 04Sale50.355,000251,7671,808Feb 05 08:09 PM
Weber BarbaraDirectorFeb 02Option Exercise1.125,3365,9767,144Feb 03 09:00 AM
GOLDSMITH MARK ASee RemarksFeb 02Option Exercise1.125,0005,6005,744Feb 03 09:01 AM
GOLDSMITH MARK ASee RemarksFeb 02Sale45.425,000227,101744Feb 03 09:01 AM
Weber BarbaraDirectorFeb 02Sale45.005,336240,1201,808Feb 03 09:00 AM